{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:27:13Z","timestamp":1789921633713,"version":"4.0.1"},"reference-count":43,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>X-linked hypophosphatemia (XLH) is a rare genetic disorder that results in increased plasma levels of fibroblast growth factor 23 (FGF23). Several studies have demonstrated a direct association between FGF23 and cardiovascular mortality in cohorts of patients with chronic renal failure. However, in patients with XLH, studies on the cardiovascular impact of the disease are rare, with contradictory results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim was to assess whether the disease led to an increased cardiovascular risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a single-center retrospective observational study on a local cohort of adult patients with XLH. The primary endpoint was a composite endpoint of the frequency of left ventricular hypertrophy (LVH) or presence of high blood pressure. Our secondary objectives were to assess echocardiographic, pulse wave velocity, and central blood pressure data as other markers of CV health. Independently of this cohort, tissue sodium content with magnetic resonance imaging was studied in 2 patients with XLH before and after burosumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-two patients were included. Median serum phosphate was 0.57 (0.47-0.72) mmol\/L and FGF23 94 pg\/L (58-2226). Median blood pressure was 124 (115-130)\/68 (65-80) mm Hg, with only 9% of patients being hypertensive. A majority of patients (69%) had no LVH, only 1 had a left ventricular mass &amp;gt;100 g\/m\u00b2 and 25% of patients had left ventricular remodeling. Pulse wave velocity was normal in all patients. No differences in skin and muscle sodium content were observed before and after burosumab in the 2 patients who underwent sodium magnetic resonance imaging.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We found no elevated risk of developing hypertension or LVH in patients with XLH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad608","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T17:47:54Z","timestamp":1697478474000},"page":"e488-e494","source":"Crossref","is-referenced-by-count":12,"title":["Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy"],"prefix":"10.1210","volume":"109","author":[{"given":"Alexandre","family":"Bouzemane","sequence":"first","affiliation":[{"name":"Hospices Civils de Lyon, Nephrology, hypertension renal and functional exploration, H\u00f4pital Edouard Herriot , 69003, Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Vignot","sequence":"additional","affiliation":[{"name":"Rheumatology Department, CHU Edouard-Herriot , 69003 Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Derain Dubourg","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Nephrology, hypertension renal and functional exploration, H\u00f4pital Edouard Herriot , 69003, Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"De Mul","sequence":"additional","affiliation":[{"name":"Reference centre for rare calcium and phosphorus diseases, paediatric rheumatology and dermatology, rare diseases network, OSCAR, ORKID, ERKNet BOND, HFME , Bron 69029 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Molin","sequence":"additional","affiliation":[{"name":"Genetic department, Centre Hospitalier Universitaire de Caen , Caen, 14033 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Chapurlat","sequence":"additional","affiliation":[{"name":"Rheumatology Department, CHU Edouard-Herriot , 69003 Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Fontanges","sequence":"additional","affiliation":[{"name":"Rheumatology Department, CHU Edouard-Herriot , 69003 Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Delsart","sequence":"additional","affiliation":[{"name":"Cardiology functional explorations, Hopital Edouard-Herriot , 69003 Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Akbari","sequence":"additional","affiliation":[{"name":"Canada Kidney clinical research unit, London Health Sciences Centre , East London, ON, N6A 5W9 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih Han Susan","family":"Huang","sequence":"additional","affiliation":[{"name":"Canada Kidney clinical research unit, London Health Sciences Centre , East London, ON, N6A 5W9 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Canada Kidney clinical research unit, London Health Sciences Centre , East London, ON, N6A 5W9 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Bacchetta","sequence":"additional","affiliation":[{"name":"Reference centre for rare calcium and phosphorus diseases, paediatric rheumatology and dermatology, rare diseases network, OSCAR, ORKID, ERKNet BOND, HFME , Bron 69029 , France"},{"name":"University of Lyon, CarMeN Laboratory, IRIS Team, INSERM, INSERM1033, INRA, INSA Lyon , 69100, Villeurbanne , France"},{"name":"INSERM 1033, prevention of bone diseases , 69008 Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3460-2507","authenticated-orcid":false,"given":"Sandrine","family":"Lemoine","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Nephrology, hypertension renal and functional exploration, H\u00f4pital Edouard Herriot , 69003, Lyon , France"},{"name":"Reference centre for rare calcium and phosphorus diseases, paediatric rheumatology and dermatology, rare diseases network, OSCAR, ORKID, ERKNet BOND, HFME , Bron 69029 , France"},{"name":"University of Lyon, CarMeN Laboratory, IRIS Team, INSERM, INSERM1033, INRA, INSA Lyon , 69100, Villeurbanne , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"issue":"3","key":"2024011817402658200_dgad608-B1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"39","key":"2024011817402658200_dgad608-B2","doi-asserted-by":"crossref","first-page":"37419","DOI":"10.1074\/jbc.M304544200","article-title":"Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX","volume":"278","author":"Liu","year":"2003","journal-title":"J Biol Chem"},{"issue":"3","key":"2024011817402658200_dgad608-B3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.bone.2012.05.015","article-title":"FGF23 Acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1\/2\u2013SGK1 signaling pathway","volume":"51","author":"Andrukhova","year":"2012","journal-title":"Bone"},{"issue":"4","key":"2024011817402658200_dgad608-B4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism","volume":"113","author":"Shimada","year":"2004","journal-title":"J Clin Invest"},{"issue":"7","key":"2024011817402658200_dgad608-B5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.matbio.2004.09.007","article-title":"Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice","volume":"23","author":"Sitara","year":"2004","journal-title":"Matrix Biol"},{"issue":"19","key":"2024011817402658200_dgad608-B6","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation"},{"issue":"9","key":"2024011817402658200_dgad608-B7","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","article-title":"High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2024011817402658200_dgad608-B8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","article-title":"The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study","volume":"152","author":"Parker","year":"2010","journal-title":"Ann Intern Med"},{"issue":"11","key":"2024011817402658200_dgad608-B9","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 Induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"issue":"6","key":"2024011817402658200_dgad608-B10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/emmm.201303716","article-title":"FGF 23 Regulates renal sodium handling and blood pressure","volume":"6","author":"Andrukhova","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"2","key":"2024011817402658200_dgad608-B11","doi-asserted-by":"crossref","first-page":"e0147845","DOI":"10.1371\/journal.pone.0147845","article-title":"Conditional deletion of fgfr1 in the proximal and distal tubule identifies distinct roles in phosphate and calcium transport","volume":"11","author":"Han","year":"2016","journal-title":"PLoS One"},{"issue":"17-18","key":"2024011817402658200_dgad608-B12","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cca.2010.05.037","article-title":"Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin\u2013angiotensin system","volume":"411","author":"Tomaschitz","year":"2010","journal-title":"Clinica Chimica Acta"},{"key":"2024011817402658200_dgad608-B13","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.3390\/ijms20174195","article-title":"The role of fibroblast growth factor 23 in inflammation and Anemia","volume-title":"IJMS","author":"Czaya","year":"2019"},{"issue":"2","key":"2024011817402658200_dgad608-B14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","article-title":"Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community","volume":"205","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"issue":"2","key":"2024011817402658200_dgad608-B15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.05.013","article-title":"Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population","volume":"207","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"issue":"10","key":"2024011817402658200_dgad608-B16","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/ndt\/gfp205","article-title":"Relationship between circulating FGF23 and total body atherosclerosis in the community","volume":"24","author":"Mirza","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2024011817402658200_dgad608-B17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00467-012-2347-x","article-title":"Phosphate is a vascular toxin","volume":"28","author":"Shroff","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"2024011817402658200_dgad608-B18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1507\/endocrj.EJ16-0199","article-title":"Hypertension is a characteristic complication of X-linked hypophosphatemia","volume":"64","author":"Nakamura","year":"2017","journal-title":"Endocr J"},{"issue":"2","key":"2024011817402658200_dgad608-B19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00467-002-1044-6","article-title":"Hypertension in hypophosphatemic rickets\u2014role of secondary hyperparathyroidism","volume":"18","author":"Alon","year":"2003","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"2024011817402658200_dgad608-B20","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1210\/jcem.82.8.4181","article-title":"Cardiovascular abnormalities in patients with X-linked hypophosphatemia","volume":"82","author":"Nehgme","year":"1997","journal-title":"J Clin Endocrinol & Metabol"},{"issue":"6","key":"2024011817402658200_dgad608-B21","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00467-018-4180-3","article-title":"Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia","volume":"34","author":"Hern\u00e1ndez-Fr\u00edas","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"2024011817402658200_dgad608-B22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jbmr.5650050508","article-title":"Normal left ventricular performance in children with x-linked hypophosphatemic rickets: a Doppler echocardiography study","volume":"5","author":"Vered","year":"1990","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024011817402658200_dgad608-B23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/07435800.2016.1242604","article-title":"Patients with FGF23-related hypophosphatemic rickets\/osteomalacia do not present with left ventricular hypertrophy","volume":"42","author":"Takashi","year":"2017","journal-title":"Endocr Res"},{"issue":"1","key":"2024011817402658200_dgad608-B24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.kint.2018.02.017","article-title":"The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk","volume":"94","author":"Pastor-Arroyo","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"2024011817402658200_dgad608-B25","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1210\/en.2018-00174","article-title":"Increased circulating FGF23 does not lead to cardiac hypertrophy in the male hyp mouse model of XLH","volume":"159","author":"Liu","year":"2018","journal-title":"Endocrinology"},{"issue":"11","key":"2024011817402658200_dgad608-B26","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1093\/ndt\/gfab331","article-title":"Tubular phosphate handling: references from child to adulthood in the era of standardized serum creatinine","volume":"37","author":"Derain Dubourg","year":"2022","journal-title":"Nephrol Dial Transpl"},{"issue":"10","key":"2024011817402658200_dgad608-B27","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1515\/cclm-2013-0208","article-title":"Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs","volume":"51","author":"Smith","year":"2013","journal-title":"Clin Chem Lab Med (CCLM)"},{"issue":"6","key":"2024011817402658200_dgad608-B28","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s11255-013-0451-x","article-title":"FGF23 Concentrations measured using \u201cintact\u201d assays similar but not interchangeable","volume":"45","author":"Sinha","year":"2013","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"2024011817402658200_dgad608-B29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bja.2020.09.049","article-title":"Cardiac output estimation using pulse wave analysis\u2014physiology, algorithms, and technologies: a narrative review","volume":"126","author":"Saugel","year":"2021","journal-title":"Br J Anaesth"},{"issue":"8","key":"2024011817402658200_dgad608-B30","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/HJH.0000000000002081","article-title":"Current assessment of pulse wave velocity: comprehensive review of validation studies","volume":"37","author":"Milan","year":"2019","journal-title":"J. Hypertens"},{"issue":"1","key":"2024011817402658200_dgad608-B31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"2024011817402658200_dgad608-B32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.echo.2016.09.007","article-title":"Normal ranges of left atrial strain by speckle-tracking echocardiography: A systematic review and meta-analysis","volume":"30","author":"Pathan","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"2024011817402658200_dgad608-B33","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/mrm.22157","article-title":"Sodium MRI using a density-adapted 3D radial acquisition technique: density-adapted sodium MRI","volume":"62","author":"Nagel","year":"2009","journal-title":"Magn Reson Med"},{"issue":"1","key":"2024011817402658200_dgad608-B34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.ajkd.2020.11.025","article-title":"Influence of dialysate sodium prescription on skin and muscle sodium concentration","volume":"78","author":"Lemoine","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2024011817402658200_dgad608-B35","doi-asserted-by":"publisher","first-page":"e012910","DOI":"10.1161\/CIRCIMAGING.121.012910","article-title":"Tissue sodium storage in patients with heart failure: A new therapeutic target?","volume-title":"Circ: Cardiovascular Imaging","author":"Lemoine","year":"2021"},{"issue":"7","key":"2024011817402658200_dgad608-B36","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/jbmr.3992","article-title":"Hyperparathyroidism in patients with X-linked hypophosphatemia","volume":"35","author":"Lecoq","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024011817402658200_dgad608-B37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2024011817402658200_dgad608-B38","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"23","key":"2024011817402658200_dgad608-B39","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and End-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"issue":"17","key":"2024011817402658200_dgad608-B40","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"2024011817402658200_dgad608-B41","first-page":"543","article-title":"Overweight, obesity and cardiometabolic risk factors prevalence in France: the constances cohort","volume":"33","author":"Matta","year":"2020","journal-title":"Am J Hypertens"},{"key":"2024011817402658200_dgad608-B42","author":"Perrine"},{"issue":"9","key":"2024011817402658200_dgad608-B43","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0002-9149(87)91133-7","article-title":"Echocardiographic criteria for left ventricular hypertrophy: the Framingham heart study","volume":"59","author":"Levy","year":"1987","journal-title":"Am J Cardiol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad608\/54040735\/dgad608.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/2\/e488\/55521963\/dgad608.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/2\/e488\/55521963\/dgad608.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T17:41:14Z","timestamp":1705599674000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/2\/e488\/7318159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,10,16]]},"published-print":{"date-parts":[[2024,1,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad608","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,10,16]]}}}